Changing patterns of anemia management in US hemodialysis patients

American Journal of Medicine

Volumn 125, Issue 9, 2012, Pages 906-914.e9

  Freburger, Janet K ^a   Ng, Leslie J ^b   Bradbury, Brian D ^b,c   Kshirsagar, Abhijit V ^d   Brookhart, M Alan ^a,e  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b AMGEN INC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e The University of North Carolina at Chapel Hill   (United States)

Author keywords

Anemia management; Chronic kidney disease; Hemodialysis; Intravenous iron

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN; IRON;

ADULT; ANEMIA; ARTICLE; DEMOGRAPHY; DIALYSIS; DRUG DOSE INCREASE; DRUG USE; FEMALE; GEOGRAPHY; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; PRIORITY JOURNAL; RACE; SAMPLE; UNITED STATES;

EID: 84864287249     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2012.03.011     Document Type: Article

References (34)

1. L. Del Vecchio, A. Cavalli, B. Tucci, F. Locatelli Chronic kidney disease-associated anemia: new remedies Curr Opin Investig Drugs 11 9 2010 1030 1038
2. KDOQI; National Kidney Foundation KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease Am J Kidney Dis 47 5 Suppl 3 2006 S11 S145
3. J.W. Eschbach, M.H. Abdulhadi, J.K. Browne Recombinant human erythropoietin in anemic patients with end-stage renal disease Results of a phase III multicenter clinical trial Ann Intern Med 111 12 1989 992 1000
4. J.W. Eschbach, J.C. Egrie, M.R. Downing, J.K. Browne, J.W. Adamson Correction of the anemia of end-stage renal disease with recombinant human erythropoietin Results of a combined phase I and II clinical trial N Engl J Med 316 2 1987 73 78
5. A. Besarab, D.W. Coyne Iron supplementation to treat anemia in patients with chronic kidney disease Nat Rev Nephrol 6 12 2010 699 710
6. K. Chan, J. Moran, M. Hlatky, R. Lafayette Protocol adherence and the ability to achieve target haemoglobin levels in haemodialysis patients Nephrol Dial Transplant 24 6 2009 1956 1962
7. D.W. Coyne Use of epoetin in chronic renal failure JAMA 297 15 2007 1713 1716
8. T. Kapoian, N.B. O'Mara, A.K. Singh Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin J Am Soc Nephrol 19 2 2008 372 379
9. A.K. Singh, D.W. Coyne, W. Shapiro, A.R. Rizkala Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation Kidney Int 71 11 2007 1163 1171
10. D. Regidor, W.M. McClellan, R. Kewalramani, A. Sharma, B.D. Bradbury Changes in erythropoiesis-stimulating agent (ESA) dosing and haemoglobin levels in US non-dialysis chronic kidney disease patients between 2005 and 2009 Nephrol Dial Transplant 26 5 2011 1583 1591
11. D.M. Spiegel, I. Khan, M. Krishnan, T.J. Mayne Changes in hemoglobin level distribution in US dialysis patients from June 2006 to November 2008 Am J Kidney Dis 55 1 2010 113 120
12. T.B. Drueke, F. Locatelli, N. Clyne Normalization of hemoglobin level in patients with chronic kidney disease and anemia N Engl J Med 355 20 2006 2071 2084
13. M.A. Pfeffer, E.A. Burdmann, C.Y. Chen A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease N Engl J Med 361 21 2009 2019 2032
14. A.K. Singh, L. Szczech, K.L. Tang Correction of anemia with epoetin alfa in chronic kidney disease N Engl J Med 355 20 2006 2085 2098
15. J.S. Berns Are there implications from the Trial to Reduce Cardiovascular Events with Aranesp Therapy study for anemia management in dialysis patients? Curr Opin Nephrol Hypertens 19 6 2010 567 572
16. KDOQI KDOQI clinical practice guideline and clinical practice recommendatons for anemia in chronic kidney disease: 2007 update of hemoglobin target Am J Kidney Dis 50 2007 471 530
17. Centers for Medicare and Medicaid Services Modification to the National Monitoring Policy for Erythropoietic Stimulating Agents (ESAs) for End-Stage Renal Disease (ESRD) Patients Treated in Renal Dialysis Facilities, Centers for Medicare and Medicaid Services Pub 100-04 Medicare Claims Processing, Transmittal 1307 http://www.cms.gov/transmittals/downloads/R1307CP.pdf 2007 Accessed August 16, 2011
18. D.W. Coyne, T. Kapoian, W. Suki Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study J Am Soc Nephrol 18 3 2007 975 984
19. L.T. Pizzi, T.J. Bunz, D.W. Coyne, D.S. Goldfarb, A.K. Singh Ferric gluconate treatment provides cost savings in patients with high ferritin and low transferrin saturation Kidney Int 74 12 2008 1588 1595
20. H.N. Ibrahim, R.N. Foley, R. Zhang, D.T. Gilbertson, A.J. Collins Parenteral iron use: possible contribution to exceeding target hemoglobin in hemodialysis patients Clin J Am Soc Nephrol 4 3 2009 623 629
21. W.L. St Peter, G.T. Obrador, T.L. Roberts, A.J. Collins Trends in intravenous iron use among dialysis patients in the United States (1994-2002) Am J Kidney Dis 46 4 2005 650 660
22. United States Renal Data System (USRDS) Researcher's Guide to the USRDS Database 2010 ADR Edition 2011 National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases Bethesda, MD
23. United States Renal Data System (USRDS) USRDS 2009 Annual Data Report: Atlas of End-Stage Renal Disease in the United States 2009 National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases Bethesda MD
24. S.R. Searle, F.M. Speed, G.A. Milliken Population marginal means in the linear model: an alternative to least squares means Am Stat 34 4 1980 216 221
25. M.A. Pfeffer, E.A. Burdmann, C.Y. Chen Baseline characteristics in the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Am J Kidney Dis 54 1 2009 59 69
26. N.D. Vaziri, X.J. Zhou Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease Nephrol Dialysis Transplant 24 4 2009 1082 1088
27. U.C. Brewster Intravenous iron therapy in end-stage renal disease Semin Dial 19 4 2006 285 290
28. H.I. Feldman, J. Santanna, W. Guo Iron administration and clinical outcomes in hemodialysis patients J Am Soc Nephrol 13 3 2002 733 744
29. H.I. Feldman, M. Joffe, B. Robinson Administration of parenteral iron and mortality among hemodialysis patients J Am Soc Nephrol 15 6 2004 1623 1632
30. L.T. Pizzi Economic considerations in a changing anemia environment Am J Kidney Dis 52 6 Suppl 2008 S29 S33
31. T. Hasegawa, J.L. Bragg-Gresham, R.L. Pisoni Changes in anemia management and hemoglobin levels following revision of a bundling policy to incorporate recombinant human erythropoietin Kidney Int 79 3 2011 340 346
32. A.J. Collins, B. Kasiske, C. Herzog Excerpts from the United States Renal Data System 2006 Annual Data Report Am J Kidney Dis 49 1 Suppl 1 2007 A6 A7 S1-S296
33. E. Lacson Jr, J. Rogus, M. Teng, J.M. Lazarus, R.M. Hakim The association of race with erythropoietin dose in patients on long-term hemodialysis Am J Kidney Dis 52 6 2008 1104 1114
34. M.A. Brookhart, S. Schneeweiss, J. Avorn, B.D. Bradbury, J. Liu, W.C. Winkelmayer Comparative mortality risk of anemia management practices in incident hemodialysis patients JAMA 303 9 2010 857 864